Halozyme Therapeutics, Inc. (HALO) Monday reported a first-quarter loss of $15.1 million or $0.14 per share, which widened from $9.6 million or $0.10 per share in the year-ago period.
On average, eight analysts polled by Thomson Reuters expected the company to report a loss of $0.11 per share for the first quarter. Analysts' estimates typically exclude special items.
First-quarter revenues declined to $7.4 million from $7.5 million last year. Analysts expected revenues of $7.31 million for the quarter.
For comments and feedback: editorial@rttnews.com